Analysis cohorts
ALS
AMYOTROPHIC LATERAL SCLEROSIS
During the conduct of the CENTAUR trial, eligible participants were in the randomized phase from June 2017 to September 2019 and in the OLE phase from March 2018 to March 2021. CENTAUR trial eligibility criteria allowed for the stable use of riluzole and edaravone before and during the trial. Survival results for the CENTAUR PB and TURSO group in this analysis were obtained from the aforementioned ITT analysis, the methods of which have been previously described.Data from the PRO‐ACT database that were used in the preparation of this article have been volunteered by PRO‐ACT Consortium members. The process for constructing the PRO‐ACT external control group is schematically summarized in Figure Summarized process for constructing the PRO‐ACT external control group. ALSFRS‐R, Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised; PRO‐ACT, Pooled Resource Open‐Access ALS Clinical Trials; PSM, propensity score matching.To account for potential imbalance in baseline participant characteristics and other variables across trials,